<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959514</url>
  </required_header>
  <id_info>
    <org_study_id>ARE-247-101</org_study_id>
    <nct_id>NCT03959514</nct_id>
  </id_info>
  <brief_title>AT247, NovoRapid® and Fiasp® in Glucose Clamp Study</brief_title>
  <official_title>Phase I Single Dose, Randomised, Double-blind, Three-way Cross Over, Glucose Clamp Study Investigating the PK/PD and Safety of Arecor Ultra-rapid Insulin Aspart (AT247) in Comparison to NovoRapid® and Fiasp® in Participants With Type I Diabetes Mellitus (T1DM).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arecor Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arecor Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, randomised, single-centre, double-blind, single-dose, three period, balanced cross
      over study in a glucose clamp setting. The study compares the pharmacodynamic,
      pharmacokinetic and safety characteristics of AT247, NovoRapid® and Fiasp® in male
      participants with type I diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2019</start_date>
  <completion_date type="Actual">August 8, 2019</completion_date>
  <primary_completion_date type="Actual">July 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the glucose infusion rate-time curve of insulin aspart</measure>
    <time_frame>0-60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin aspart concentration-time curve from 0-60 minutes</measure>
    <time_frame>0-60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>AT247</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection 0.3 U/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoRapid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous injection 0.3 U/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fiasp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous injection 0.3 U/Kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NovoRapid</intervention_name>
    <description>Rapid acting prandial insulin aspart</description>
    <arm_group_label>AT247</arm_group_label>
    <arm_group_label>Fiasp</arm_group_label>
    <arm_group_label>NovoRapid</arm_group_label>
    <other_name>NovoLog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fiasp</intervention_name>
    <description>Fast acting prandial insulin aspart</description>
    <arm_group_label>AT247</arm_group_label>
    <arm_group_label>Fiasp</arm_group_label>
    <arm_group_label>NovoRapid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AT247</intervention_name>
    <description>Ultra rapid acting prandial insulin aspart</description>
    <arm_group_label>AT247</arm_group_label>
    <arm_group_label>Fiasp</arm_group_label>
    <arm_group_label>NovoRapid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          1. Diagnosis type I Diabetes Mellitus for at least 12 months

          2. Receiving treatment with multiple daily insulin injections or insulin pump therapy for
             at least 12 months

          3. Fasting C-peptide concentration ≤8.5% (≤69 mmol/mol) at screening

          4. BMI 18.5-35.0 kg/m2

        Exclusion Criteria include:

          1. known or suspected hypersensitivity to Investigational Medicinal Products

          2. clinically significant concomitant disease or abnormal lab values

          3. supine systolic BP outside range 95-140 mmHg and/or diastolic BP greater than 90 mmHg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Centre</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

